Impact Biomedical Inc. financial data

Symbol
IBO on NYSE
Location
1400 Broadfield Blvd., Suite 130, Houston, TX
State of incorporation
Nevada
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.74 %
Return On Equity -15.7 %
Return On Assets -10.1 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 10M shares
Common Stock, Shares, Outstanding 10M shares -99.7%
Common Stock, Value, Issued 10K USD -92%
Weighted Average Number of Shares Outstanding, Basic 10M shares -85.8%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 1.02M USD -72.1%
Selling and Marketing Expense 18K USD +80%
Costs and Expenses 1.08M USD +21.3%
Operating Income (Loss) -3.61M USD +37.9%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -4.32M USD +21.1%
Net Income (Loss) Attributable to Parent -4.56M USD -17.6%
Earnings Per Share, Basic -0.23 USD/shares -350%
Earnings Per Share, Diluted -0.23 USD/shares -350%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 2K USD -33.3%
Accounts Receivable, after Allowance for Credit Loss, Current 128K USD
Assets, Current 307K USD -11.8%
Property, Plant and Equipment, Net 284K USD -2.07%
Goodwill 25.1M USD 0%
Assets 44.1M USD -4.08%
Accounts Payable, Current 986K USD +228%
Accrued Liabilities, Current 61K USD
Liabilities, Current 14.5M USD +20.3%
Deferred Income Tax Liabilities, Net 3.24M USD 0%
Liabilities 16.4M USD +18.4%
Retained Earnings (Accumulated Deficit) -14.8M USD -40.2%
Stockholders' Equity Attributable to Parent 23.4M USD -15.4%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 26.4M USD -14.1%
Liabilities and Equity 44.1M USD -4.08%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -712K USD +29.8%
Net Cash Provided by (Used in) Financing Activities 713K USD -29.9%
Common Stock, Shares Authorized 4B shares 0%
Common Stock, Shares, Issued 10M shares -99.7%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 1K USD
Deferred Tax Assets, Gross 3.55M USD +27.4%
Depreciation 2K USD 0%
Property, Plant and Equipment, Gross 293K USD 0%
Deferred Tax Assets, Operating Loss Carryforwards 2.09M USD +29.5%
Preferred Stock, Shares Issued 60.5M shares
Preferred Stock, Shares Authorized 100M shares
Additional Paid in Capital 38.1M USD
Preferred Stock, Shares Outstanding 60.5M shares
Depreciation, Depletion and Amortization 280K USD 0%
Interest Expense 718K USD +125%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares